| P50 | author | Philip Bruggmann | Q56525694 |
| P2093 | author name string | P Bruggmann | |
| P2860 | cites work | Outcomes of treatment for hepatitis C virus infection by primary care providers | Q24601722 |
| | Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews | Q24630669 |
| | Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection | Q27490862 |
| | Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study | Q27491349 |
| | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 |
| | A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment | Q30540697 |
| | Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States | Q33819963 |
| | The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings | Q33834958 |
| | Successful integration of hepatitis C evaluation and treatment services with methadone maintenance | Q33858467 |
| | Hepatitis C management by addiction medicine physicians: results from a national survey | Q34090853 |
| | Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement | Q34293132 |
| | Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat | Q34628400 |
| | Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors | Q34719654 |
| | Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada | Q34789013 |
| | Barriers to accessing care in patients with chronic hepatitis C: the impact of depression | Q34913362 |
| | Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United States | Q35008495 |
| | Hepatitis C in HIV-infected individuals: cure and control, right now. | Q35047562 |
| | Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. | Q35596037 |
| | Treatment of chronic hepatitis C in Canadian prison inmates | Q36073864 |
| | Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. | Q36376962 |
| | Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment | Q36476423 |
| | Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity. | Q36609890 |
| | Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. | Q36619642 |
| | Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study | Q45413375 |
| | Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. | Q45497809 |
| | Adherence to hepatitis C treatment in recovering heroin users maintained on methadone | Q46126021 |
| | Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy | Q46306874 |
| | Knowledge of and interest in hepatitis C treatment at a methadone clinic | Q48494486 |
| | Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use. | Q50567670 |
| | Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. | Q50953377 |
| | Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. | Q51865940 |
| | Need-adapted HCV-treatment setting for injection drug users. | Q52294512 |
| | Outreach screening of drug users for cirrhosis with transient elastography. | Q52297787 |
| | Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility | Q57701087 |
| | Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. | Q36744166 |
| | The depiction of stigmatization in research about hepatitis C. | Q36940146 |
| | Capacity enhancement of hepatitis C virus treatment through integrated, community-based care | Q37136533 |
| | Hepatitis C among clients of health care for the homeless primary care clinics | Q37206722 |
| | Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program | Q37216987 |
| | Limited uptake of hepatitis C treatment among injection drug users | Q37238205 |
| | Hepatitis C treatment for injection drug users: a review of the available evidence | Q37546106 |
| | Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support | Q37738838 |
| | Risk of Hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: a systematic review | Q37812971 |
| | Management of HCV and HIV infections among people who inject drugs | Q37946171 |
| | What is killing people with hepatitis C virus infection? | Q37970623 |
| | Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere | Q39559440 |
| | The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam | Q39707313 |
| | Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland | Q39727720 |
| | Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons | Q39734480 |
| | Place of residence and distance to medical care influence the diagnosis of hepatitis C: a population-based study | Q39743023 |
| | Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. | Q39808476 |
| | Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. | Q39820916 |
| | Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States☆☆☆ | Q39844102 |
| | Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. | Q39874376 |
| | Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals | Q39910287 |
| | Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. | Q39922039 |
| | Public health impact of antiviral therapy for hepatitis C in the United States | Q39939298 |
| | Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk | Q40021862 |
| | Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. | Q40547978 |
| | Perceived barriers to hepatitis C therapy for patients receiving opioid agonist treatment | Q42658701 |
| | A watershed moment in the treatment of hepatitis C. | Q42976990 |
| | Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. | Q42980109 |
| | Overcoming barriers to care for hepatitis C. | Q42981735 |
| | FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study | Q42984796 |
| | A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance | Q42986145 |
| | Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs | Q42996717 |
| | Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes | Q42997466 |
| | Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy | Q43000888 |
| | Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project | Q43001228 |
| | Management of hepatitis C patients by primary care physicians in the USA: results of a national survey | Q43034294 |
| | Treatment of chronic hepatitis C in a state correctional facility | Q43042164 |
| | Hepatitis C: studying stigma | Q43493544 |
| | Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs | Q44105883 |
| | The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users | Q44163628 |
| | Market uptake of new antiviral drugs for the treatment of hepatitis C. | Q44557658 |
| | The impact of injecting drug use status on hepatitis C-related referral and treatment | Q45193444 |
| | Chronic Hepatitis C virus infection in Swiss primary care practices: low case loads-high barriers to treatment? | Q45367121 |
| | Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia | Q45373064 |
| P433 | issue | 12 | |
| P921 | main subject | hepatitis C | Q154869 |
| P304 | page(s) | 829-835 | |
| P577 | publication date | 2012-10-01 | |
| P1433 | published in | Journal of Viral Hepatitis | Q15749962 |
| P1476 | title | Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers | |
| P478 | volume | 19 | |